Sell-side analysts still seem to be nervous about the near-term future of the spine market, but investors haven't let that scare them away from NuVasive (NASDAQ:NUVA). With new products and a focused OUS strategy re-accelerating growth and management laying out some bold ambitions for the next five years, these shares have more than doubled over the past year. This move doesn't have the shares looking particularly cheap these days, but if expectations for ortho M&A stay in place and NuVasive continues to take share from large rivals like Johnson & Johnson (NYSE:JNJ) and Medtronic (NYSE:MDT), I don't think the Street will get all that concerned about valuation.
Turbulence In The Spine Market Isn't Going...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|